Lapatinib Tablet 250 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 250 mg

Reference Brands: Tykerb® (EU & US)

Category: Oncology Cancer Care

Lapatinib 250 mg film-coated tablets, an oral HER2 and EGFR kinase inhibitor for HER2-positive breast cancer. For oncology pharmacies, hospital buyers, importers and distributors.

Product Description:

Lapatinib is an oral tyrosine kinase inhibitor that blocks two related receptors at once, HER2 and EGFR. It works inside the cell at the kinase domain, unlike the antibodies used in HER2-positive disease, which act on the cell surface. The 250 mg film-coated tablet matches the reference product, and each daily dose uses several tablets, so packs are large.

Lapatinib is used for HER2-positive advanced or metastatic breast cancer. It is given with capecitabine after earlier therapy that included trastuzumab, or with an aromatase inhibitor in hormone receptor-positive disease. The whole daily dose is taken at once, at least one hour before or after food, because food raises absorption sharply. Liver toxicity carries a warning, so liver tests are checked. Cardiac ejection fraction, QT interval and diarrhoea are monitored. Strong CYP3A4 inhibitors, inducers and grapefruit juice are avoided.

Sourcing notes. A generic needs a CTD dossier with bioequivalence data, and oncology tenders often ask which reference product was used. The active is lapatinib ditosylate monohydrate, with strength stated as base, so check that label and certificate match. Ask for long-term stability data for your climatic zone, including IVb for hot, humid markets. Confirm the tablet count per pack against the daily regimen. Request a batch CoA, a current GMP certificate and a CoPP. Lapatinib is prescription-only and kept at room temperature. State strength, pack, annual volume and target country.